Search Results

You are looking at 61 - 70 of 91 items for :

  • "cytoreduction" x
  • Refine by Access: All x
Clear All
Full access

PTCH1-GLI1 Fusion–Positive Ovarian Tumor: Report of a Unique Case With Response to Tyrosine Kinase Inhibitor Pazopanib

Rofieda R. Alwaqfi, Megan I. Samuelson, Natalya N. Guseva, Michelle Ouyang, Aaron D. Bossler, and Deqin Ma

necrotic hepatic metastases (arrows) 2 months post pazopanib therapy. The patient underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy, lymph node dissection, staging biopsies, and omentectomy and achieved optimal cytoreduction

Full access

Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Mustafa A. Arain, Yi-Jen Chen, Kristen K. Ciombor, Stacey A. Cohen, Harry S. Cooper, Dustin A. Deming, Ignacio Garrido-Laguna, Jean L. Grem, Sarah E. Hoffe, Joleen Hubbard, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina S. Pedersen, Leonard B. Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Alyse Johnson-Chilla, Kristina M. Gregory, and Lisa A. Gurski

peritoneal metastases is palliative and primarily consists of systemic therapy (see “Systemic Therapy for Metastatic Disease,” next section). For resectable peritoneal carcinomatosis, surgical cytoreduction may be considered. For peritoneal metastases that

Full access

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

Margaret R. O'Donnell, Martin S. Tallman, Camille N. Abboud, Jessica K. Altman, Frederick R. Appelbaum, Daniel A. Arber, Vijaya Bhatt, Dale Bixby, William Blum, Steven E. Coutre, Marcos De Lima, Amir T. Fathi, Melanie Fiorella, James M. Foran, Steven D. Gore, Aric C. Hall, Patricia Kropf, Jeffrey Lancet, Lori J. Maness, Guido Marcucci, Michael G. Martin, Joseph O. Moore, Rebecca Olin, Deniz Peker, Daniel A. Pollyea, Keith Pratz, Farhad Ravandi, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Eunice S. Wang, Matthew Wieduwilt, Kristina Gregory, and Ndiya Ogba

superiority of SDAC or HiDAC. Treatments for induction failure (see following discussion) may also be considered. For patients with significant cytoreduction and a low percentage of residual blasts, SDAC with idarubicin or daunorubicin is recommended. SDAC

Full access

Spine Radiosurgery in the Management of Renal Cell Carcinoma Metastases

Neil K. Taunk, Daniel E. Spratt, Mark Bilsky, and Yoshiya Yamada

. Role of RT in RCC RT has little role in treating primary localized RCC. Surgery is the primary modality for localized RCC and select metastatic cases for cytoreduction. 6 Two prospective trials examining preoperative RT showed no significant survival

Full access

Quality Measurement in Cancer Care: A Review and Endorsement of High-Impact Measures and Concepts

Thomas A. D’Amico, Lindsey A.M. Bandini, Alan Balch, Al B. Benson III, Stephen B. Edge, C. Lyn Fitzgerald, Robert J. Green, Wui-Jin Koh, Michael Kolodziej, Shaji Kumar, Neal J. Meropol, James L. Mohler, David Pfister, Ronald S. Walters, and Robert W. Carlson

therapy (ADT), which may last 18 to 36 months. 44 – 46 The benefit of ADT may be due to early treatment of micrometastatic disease and cytoreduction of primary disease. Target volume reduction, when combined with advanced conformal radiation planning and

Full access

NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022

Featured Updates to the NCCN Guidelines

Deborah K. Armstrong, Ronald D. Alvarez, Floor J. Backes, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Viola C. Chitiyo, Mihaela Cristea, Maria DeRosa, Eric L. Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath III, Gary Leiserowitz, Joyce Liu, Lainie Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, Sanja Percac-Lima, Steven W. Remmenga, John Schorge, Daphne Stewart, Premal H. Thaker, Roberto Vargas, Andrea Wahner Hendrickson, Theresa L. Werner, Emese Zsiros, Mary A. Dwyer, and Lisa Hang

several options for patients with recurrent LGSC (see LCOC-7 , page 975). Secondary cytoreduction can be considered for patients with a long disease-free interval, isolated masses rather than diffuse carcinomatosis on imaging, and/or bowel obstruction

Full access

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021

Featured Updates to the NCCN Guidelines

Daniel A. Pollyea, Dale Bixby, Alexander Perl, Vijaya Raj Bhatt, Jessica K. Altman, Frederick R. Appelbaum, Marcos de Lima, Amir T. Fathi, James M. Foran, Ivana Gojo, Aric C. Hall, Meagan Jacoby, Jeffrey Lancet, Gabriel Mannis, Guido Marcucci, Michael G. Martin, Alice Mims, Jadee Neff, Reza Nejati, Rebecca Olin, Mary-Elizabeth Percival, Thomas Prebet, Amanda Przespolewski, Dinesh Rao, Farhad Ravandi-Kashani, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Kendra Sweet, Pankit Vachhani, Matthew Wieduwilt, Kristina M. Gregory, Ndiya Ogba, and Martin S. Tallman

in course 1, and then twice weekly in weeks 2 through 4 during courses 2 through 5. High-risk patients could receive an initial dose of gemtuzumab ozogamicin (GO) at 6 mg/m 2 for cytoreduction. Comparison between the ATRA + ATO group and the AIDA

Full access

Identifying Older Patients With Acute Myeloid Leukemia Who May Be Candidates for Reduced-Intensity Hematopoietic Cell Transplantation

Boglarka Gyurkocza and Frederick R. Appelbaum

cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases . Blood 1998 ; 32 : 756 – 763 . 40. Spitzer TR McAfee S Sackstein R

Full access

Selecting Targeted Therapies for Patients With Renal Cell Carcinoma

Elizabeth R. Plimack and Gary R. Hudes

of surgery would no longer be cure but rather cytoreduction. Metastatic Clear Cell RCC: First-Line Treatment Most patients with RCC for whom targeted therapy is considered have metastatic disease. Of these, clear cell histology is the most common

Full access

Evolving Paradigms in the Treatment of Newly Diagnosed Multiple Myeloma

Alessandra Larocca and Antonio Palumbo

studies highlight the role of obtaining a profound cytoreduction, which potentially translates into improved long-term outcomes. Hematopoietic Stem Cell Transplantation ASCT is considered the gold standard for patients with MM younger than 65 years